In a recent development within the California state court, a group of investors, including a screenwriter from “Toy Story,” have agreed to dismiss their claims against a Los Angeles-based law firm and its name partner in an ongoing $87 million fraud lawsuit targeting a bioscience company. Concurrently, the law firm has withdrawn its anti-SLAPP motion filed in response to the suit.
The investors had alleged that the law firm played a role in the purported fraudulent activities of the bioscience company. However, the specifics of the allegations against the firm and the reasons for the dismissal have not been publicly disclosed.
This case is part of a broader trend of legal actions against bioscience companies. For instance, Skye Bioscience, Inc. is currently facing a class-action lawsuit from investors who claim the company misled them about the safety and prospects of a key drug candidate before its initial public offering. The lawsuit alleges that Skye presented an overly optimistic picture of its clinical trials, leading to significant financial losses for investors when the company later announced the discontinuation of the trial due to safety concerns. More details on this case can be found here.
Similarly, Twist Bioscience Corporation is embroiled in a securities fraud class action. The plaintiffs allege that Twist and certain senior management misrepresented the company’s ability to produce synthetic DNA at higher quality and lower cost than competitors. A recent court decision denied the defendants’ motion to dismiss, allowing the case to proceed to discovery. Further information is available here.
These cases underscore the increasing scrutiny and legal challenges faced by bioscience companies, highlighting the importance of transparency and accurate disclosures to investors.